Advertisement

Drug Design for Cardiovascular Therapeutics: Activation of DA1 Receptors

  • Barry A. Berkowitz
Chapter
Part of the Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology book series

Abstract

The therapeutic rationale for the utility of drugs to be designed to selectively stimulate DA receptors was that such agents would be selective vasodilators. Because DA receptors were known to mediate vasodilatation and were believed to have a selective distribution in vascular beds such as the renal vasculature, it followed that these drugs might reduce blood pressure or load on the heart without an equivalent decline in kidney blood flow or renal function (Hahn et al., 1982; Goldberg and Raijfer, 1985). Thus, potential therapeutic targets were hypertension, congestive heart failure and conditions associated with reduced renal blood flow and increased renal vascular resistance.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ackerman, D. M., Weinstock, J. W., Wiebelhaus, V. D. and Berkowitz, B. (1982). Renal vasodilators and hypertension. Drug Dev. Res., 2, 283–297CrossRefGoogle Scholar
  2. Berkowitz, B. A., Arleth, A. J., Sung, C.-P., Kruse, L. I., DeWolf, W. E. and Ohlstein, E. H. (1988). Effects of the novel dopamine-β-hydroxylase inhibitor, SK&F 102698, on catecholamine and blood pressure in spontaneously hypertensive rats. J. Pharmac. Exp. Ther. (in press)Google Scholar
  3. Berkowitz, B. A. and Ohlstein, E. H. (1984). Cardiovascular dopamine receptors: Recent advances in agonists and antagonists of the DA1-receptor. J. Cardiovasc. Pharmac., 6, S559–S563CrossRefGoogle Scholar
  4. Berkowitz, B. A. and Ohlstein, E. H. (1987). Fenoldopam. In A. Scriabine (Ed.), New Cardiovascular Drugs 1987, Raven Press, New York, pp. 237–250Google Scholar
  5. DeVries, G. W., Mobasser, A. and Wheeler, L. A. (1986). Stimulation of endogenous cyclic AMP levels in ciliary body by SK&F 82526, a novel dopamine receptor agonist. Curr. Eye Res., 5, 449–455CrossRefGoogle Scholar
  6. Dupont, A. G., Lefebvre, R. A. and Vanderniepen, P. (1987). Influence of the dopamine receptor agonists fenoldopam and quinperole in the rat superior mesenteric vascular bed. Br. J. Pharmac., 91, 493–501CrossRefGoogle Scholar
  7. Flaim, K. E., Gessner, G. A., Crooke, S. T., Sarau, H. M. and Weinstock, J. (1985). Binding of a novel dopaminergic agonist radioligand and (3H) fenoldopam (SK&F 82526) to D1 receptors in rat striatum. Life Sci., 36, 1427–1436PubMedCrossRefGoogle Scholar
  8. Foley, J. J. and Sarau, H. M. (1984). Adrenergic binding studies of SK&F 82526 and its enantiomers. Fed. Proc., 43, 555Google Scholar
  9. Goldberg, L., Kohli, J. P. and Glock, D. (1986). DA1 agonist versus alpha-adrenoceptor antagonist activity of fenoldopam in the dog. Fed. Proc., 45, 195Google Scholar
  10. Goldberg, L. and Raijfer, S. I. (1985). Dopamine receptors: Applications in clinical cardiology. Circulation, 72, 245–248PubMedCrossRefGoogle Scholar
  11. Hahn, R. A., Wardell, J. R., Sarau, H. M. and Ridley, P. T. (1982). Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmac. Exp. Ther., 233, 305–313Google Scholar
  12. Harvey, J. N., Worth, D. P., Brown, J. and Lee, M. R. (1986). Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. Br. J. Clin. Pharmac., 21, 53–61CrossRefGoogle Scholar
  13. Hughes, A., Thorn, S., Martin, G., Redman, D., Hasan, S. and Sever, P. (1986). The action of a dopamine (DA1) receptor agonist, fenoldopam, in human vasculature in vivo and in vitro. Br. J. Clin. Pharmac, 22, 535–540CrossRefGoogle Scholar
  14. Lappe, R., Todt, J., and Wendt, R. (1986). Effect of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J. Pharmac. Exp. Ther., 236, 187–191Google Scholar
  15. Lokhandwala, M. F. and Sabouni, M. H. (1985). Ganglionic dopamine receptors as mediators of the inhibition of neurogenic vasoconstriction produced by fenoldopam. J. Autonom. Pharmac., 5, 301–305CrossRefGoogle Scholar
  16. Molinoff, P., Brimijoin, S. and Axelrod, J. (1972). Induction of dopamine β-hydroxylase and tyrosine hydroxylase in rat hearts and sympathetic ganglia. J. Pharmac. Exp. Ther., 182, 116–129Google Scholar
  17. Ohlstein, E. H., Kruse, L. I., Ezekiel, M., Sherman, S. S., Erickson, R., DeWolfe, W. E. and Berkowitz, B. A. (1987). Cardiovascular effects of a new potent dopamine β-hydroxylase inhibitor in spontaneously hypertensive rats. J. Pharmac. Exp. Ther., 241, 554–559Google Scholar
  18. Ohlstein, E. H., Zabko-Potapovich, B. and Berkowitz, B. A. (1984). Studies on vascular dopamine receptors with dopamine receptor agonist: SK&F 82526. J. Pharmac. Exp. Ther., 229, 433–439Google Scholar
  19. Ohlstein, E. H., Zabko-Potapovich, B. and Berkowitz, B. A. (1985). The DA1 receptor agonist fenoldopam (SK&F 82526) is also an α 2-adrenoceptor antagonist. Eur. J. Pharmac., 118, 321–329CrossRefGoogle Scholar
  20. Roffman, M., Friedman, L. and Goldstein, M. (1973). The effect of acute and chronic swim stress on dopamine β-hydroxylase activity. Life Sci., 12, 369–376CrossRefGoogle Scholar
  21. Sole, M. J., Kamble, A. B. and Hussain, M. M. (1977). A possible change in the rate limiting steps for cardiac norepinephrine synthesis in the cardiomyopathetic Syrian hamster. Clin. Res., 41, 814–817Google Scholar
  22. Stote, R., Dubb, J., Familiar, R., Erb, B. and Alexander, F. (1983). A new oral vasodilator SK&F 82526. Clin. Pharmac. Ther., 34, 309–315CrossRefGoogle Scholar
  23. Szabo, B., Hedler, L. and Starke, K. (1986). Dopamine receptor agonist and alpha-2 adrenoceptor antagonist effects of fenoldopam in rabbits. J. Pharmac. Exp. Ther., 239, 881–886Google Scholar
  24. Trajkov, T., Berkowitz, B. A. and Spector, S. (1974). Catechol-o-methyltransferase and dopamine β-hydroxylase activity in the blood vessels of hypertensive rats. Blood Vessies, 11, 101–109Google Scholar
  25. Weiner, N. (1985). In Gilman, A. G., Goodman, L. S., Rall, T. W. and Murad, F. (Eds.) The Pharmacological Basis of Therapeutics, Macmillan., New York, p. 210Google Scholar

Copyright information

© Barry A. Berkowitz 1988

Authors and Affiliations

  • Barry A. Berkowitz

There are no affiliations available

Personalised recommendations